• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    6/30/23 1:37:38 PM ET
    $APYX
    $BXRX
    $CALC
    $CBAY
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $APYX alert in real time by email

    Gainers

    • Baudax Bio (NASDAQ:BXRX) shares increased by 130.7% to $1.2 during Friday's regular session. Trading volume for this security as of 13:37 EST is 93.9 million, which is 10027.5% of its average full-day volume over the last 100 days. The company's market cap stands at $7.2 million.
    • CymaBay Therapeutics (NASDAQ:CBAY) stock increased by 41.61% to $11.1. The current volume of 13.9 million shares is 855.6% of CymaBay Therapeutics's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $1.0 billion.
    • Renalytix (NASDAQ:RNLX) stock increased by 41.14% to $2.92. Trading volume for this security as of 13:37 EST is 29.7 million, which is 50575.9% of its average full-day volume over the last 100 days. The company's market cap stands at $137.0 million.
    • Cyteir Therapeutics (NASDAQ:CYT) shares increased by 39.06% to $2.67. As of 13:37 EST, this security is trading at a volume of 8.6 million shares, making up 20968.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $94.8 million.
    • Enochian BioSciences (NASDAQ:ENOB) stock rose 37.47% to $0.55. The current volume of 263.5K shares is 249.3% of Enochian BioSciences's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $32.4 million.
    • Gracell Biotechnologies (NASDAQ:GRCL) stock rose 32.5% to $3.98. Trading volume for Gracell Biotechnologies's stock is 428.4K as of 13:37 EST. This is 161.9% of its average full-day volume over the last 100 days. The company's market cap stands at $269.1 million.

    Losers

    • Apyx Medical (NASDAQ:APYX) shares declined by 27.5% to $4.86 during Friday's regular session. As of 13:37 EST, Apyx Medical's stock is trading at a volume of 1.1 million, which is 465.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $168.2 million.
    • Surgalign Holdings (NASDAQ:SRGA) shares declined by 27.08% to $0.2. Trading volume for Surgalign Holdings's stock is 5.0 million as of 13:37 EST. This is 195.8% of its average full-day volume over the last 100 days. The company's market cap stands at $1.8 million.
    • Unicycive Therapeutics (NASDAQ:UNCY) stock declined by 24.55% to $1.25. As of 13:37 EST, Unicycive Therapeutics's stock is trading at a volume of 692.1K, which is 262.9% of its average full-day volume over the last 100 days. The company's market cap stands at $18.9 million.
    • PetVivo Hldgs (NASDAQ:PETV) shares decreased by 20.59% to $1.89. As of 13:37 EST, PetVivo Hldgs's stock is trading at a volume of 114.2K, which is 690.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.0 million. The company's, Q4 earnings came out yesterday.
    • CalciMedica (NASDAQ:CALC) stock declined by 15.25% to $4.11. The market value of their outstanding shares is at $23.2 million.
    • Genfit (NASDAQ:GNFT) shares fell 14.57% to $3.46. Genfit's stock is trading at a volume of 4.2 million shares as of 13:37 EST. This is 35658.4% of its average full-day volume over the last 100 days. The company's market cap stands at $172.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APYX
    $BXRX
    $CALC
    $CBAY

    CompanyDatePrice TargetRatingAnalyst
    Apyx Medical Corporation
    $APYX
    3/11/2026$6.00Neutral → Buy
    BTIG Research
    CalciMedica Inc.
    $CALC
    1/29/2026Buy → Neutral
    H.C. Wainwright
    Apyx Medical Corporation
    $APYX
    12/16/2025$6.00Buy
    Roth Capital
    Apyx Medical Corporation
    $APYX
    11/14/2025Mkt Perform → Mkt Outperform
    Citizens JMP
    Apyx Medical Corporation
    $APYX
    11/12/2025$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    GENFIT S.A.
    $GNFT
    8/19/2025$9.00Buy
    H.C. Wainwright
    Unicycive Therapeutics Inc.
    $UNCY
    4/21/2025$6.00Buy
    Guggenheim
    Apyx Medical Corporation
    $APYX
    10/17/2024Neutral
    BTIG Research
    More analyst ratings

    $APYX
    $BXRX
    $CALC
    $CBAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Apyx Medical upgraded by BTIG Research with a new price target

    BTIG Research upgraded Apyx Medical from Neutral to Buy and set a new price target of $6.00

    3/11/26 8:28:33 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    CalciMedica downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CalciMedica from Buy to Neutral

    1/29/26 7:00:08 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Apyx Medical with a new price target

    Roth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00

    12/16/25 8:46:26 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

    Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 LA JOLLA, Calif., March 3, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic

    3/3/26 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    SEC Filings

    View All

    SEC Form 8-K filed by CalciMedica Inc.

    8-K - CalciMedica, Inc. (0001534133) (Filer)

    3/18/26 4:30:35 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PetVivo Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement

    8-K - PetVivo Holdings, Inc. (0001512922) (Filer)

    3/16/26 5:30:59 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by CalciMedica Inc.

    EFFECT - CalciMedica, Inc. (0001534133) (Filer)

    3/12/26 12:15:06 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc converted options into 974,809 shares and bought $77,999 worth of shares (154,840 units at $0.50) (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:39 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought $485,355 worth of shares (718,358 units at $0.68) and converted options into 4,033,209 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:14 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

    Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity

    8/14/24 12:53:53 PM ET
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Citronowicz Moshe exercised 37,000 shares at a strike of $1.80, increasing direct ownership by 8% to 493,504 units (SEC Form 4)

    4 - Apyx Medical Corp (0000719135) (Issuer)

    3/17/26 6:27:04 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Lai John was granted 72,282 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/11/26 1:19:33 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026

    MINNEAPOLIS, MN, US, Feb. 17, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTC ID: PETVW)), and its wholly owned subsidiaries PetVivo Animal Health and PetVivo AI, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported financial and operational results for the third quarter and first nine months of its fiscal year 2026 ended December 31, 2025. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q3 Operational Highlights Signed an exclusive 10-ye

    2/17/26 4:30:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $BXRX
    $CALC
    $CBAY
    Leadership Updates

    Live Leadership Updates

    View All

    Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors

    MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company's Board of Directors. "We are honored to welcome Josh Ruben to our Board of Directors," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-b

    10/28/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

    Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t

    6/6/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    5/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care